PMV Pharmaceuticals Inc. (PMVP) News
Filter PMVP News Items
PMVP News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest PMVP News From Around the Web
Below are the latest news stories about PMV PHARMACEUTICALS INC that investors may wish to consider to help them evaluate PMVP as an investment opportunity.
PMV Pharmaceuticals Inc (PMVP) Reports Q3 2023 Financial Results and Corporate UpdatesKey Clinical Progress and Financial Metrics |
PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate HighlightsUpdated data from Phase 1 PYNNACLE clinical trial of PC14586 presented at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics demonstrated responses across multiple tumor types with median duration of response of seven monthsAn overall response rate of 38% observed at the recommended Phase 2 dose of 2000 mg daily for the intended Phase 2 population of TP53 Y220C and KRAS wild-type patientsRegistrational Phase 2 clinical trial expected to initiate in Q1 2024O |
PMV Pharmaceuticals, Inc. (PMVP) Loses -70.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerThe heavy selling pressure might have exhausted for PMV Pharmaceuticals, Inc. (PMVP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C MutationUpdated PC14586 Phase 1 data presented today as a late-breaking poster at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsConfirmed responses observed in multiple tumor types including ovarian, breast, prostate, lung, and endometrial cancer with median duration of response of seven monthsConfirmed overall response rate of 38% at Recommended Phase 2 Dose of 2000 mg daily (6/16 evaluable patients) reflective of the planned Phase 2 patient population (TP53 Y |
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL WebinarPRINCETON, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that it will present updated Phase 1 data from the ongoing Phase 1/2 PYNNACLE study of PC14586 in a late-breaking poster session at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023, i |
Wall Street Analysts See a 239.26% Upside in PMV Pharmaceuticals, Inc. (PMVP): Can the Stock Really Move This High?The average of price targets set by Wall Street analysts indicates a potential upside of 239.3% in PMV Pharmaceuticals, Inc. (PMVP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
We're Not Very Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although... |
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsLate-breaking poster presentation to highlight updated Phase 1 clinical data of PC14586, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors that have a TP53 Y220C mutationCompany to host KOL webinar on October 12, 2023 to review data and provide regulatory update PRINCETON, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumo |
Wall Street Analysts Think PMV Pharmaceuticals, Inc. (PMVP) Could Surge 182.64%: Read This Before Placing a BetThe average of price targets set by Wall Street analysts indicates a potential upside of 182.6% in PMV Pharmaceuticals, Inc. (PMVP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
PMV Pharmaceuticals, Inc. (PMVP)'s Technical Outlook is Bright After Key Golden CrossWhen a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react? |